Ysios Capital invested in Mineralys Therapeutics from its third fund, Ysios BioFund III, participating in a $118 million financing round in July 2022, and has continued to support the company in its IPO. The IPO of Mineralys represents a new milestone for Ysios Capital, being the eighth company from the Ysios funds to go public on the NASDAQ and the second from its third fund, just 8 months after the initial investment.

Mineralys Therapeutics (NASDAQ: MLYS), based in Pennsylvania, USA, is a clinical-stage biotechnology company specializing in the development of an innovative therapeutic solution for the treatment of resistant hypertension, for which there is currently no effective treatment.

"We are very proud of this new IPO of one of our investee companies. The oversubscription of the Mineralys IPO is particularly remarkable in the current market situation. Undoubtedly the innovation of the drug to treat resistant hypertension and the clinical data obtained so far are at the forefront," said Joël Jean-Mairet, partner at Ysios Capital and head of the investment in Mineralys.

Ysios Capital is a leading Spanish venture capital firm that provides financing to highly innovative life science companies developing treatments for indications with a high unmet medical need. They have offices in San Sebastian and Barcelona. Founded in 2008, it has more than 400 million euros in assets under management through its three funds.

Photo: Joël Jean-Mairet, Ysios Capital